APTI ijopp - Indian Journal of Pharmacy Practice
APTI ijopp - Indian Journal of Pharmacy Practice APTI ijopp - Indian Journal of Pharmacy Practice
Indian J. Pharm. Pract. 1(2), Jan-Mar, 2009Figure 2: Receiver Operator Curve (ROC) for CD4 ValuesReceiver Operator Curve (ROC) for CD4 Values1Sensitivity0.80.60.40.2CD4= 400CD4= 350CD4= 300CD4= 250CD4= 20000 0.1 0.2 0.3 0.4 0.51- SpecificityReferences1. Fletcher V, Kakuda NK, Collier AC. Human Mehta K, Solomon S. et.al. Changes in Totalimmunodeficiency virus infection. In: Dipiro TJ, Lymphocyte Count (TLC) as a surrogate for changesTallbert LR , Yee CG, Matzke RG, Wells GB, Poseyin CD4 count following initiation of HAART:LM, editors. Pharmacotherapy: A Pathophysiolo-Implications for monitoring in resource – limitedthgical approach. 5 ed. United States of America:settings. J Acquir Immune Defic Syndr 2004; 36:McGraw-Hill Medical publishing division; 2002:567-575.2151-2174.2. Kojic EM, Carpenter CJ. Initiating antiretroviral9. National AIDS control organization (India)therapy. Available from University of California, HIV/AIDS epidemiological surveillance &San Francisco, CA, (US); hivinsite; 2006.estimation report. New Delhi:20053. U.S Food and drug administration (US).FDA 10. World Bank (US).World development indicators,approves the First Once-a-Day Three-Drug India- data and statistics. Washington: DataCombination Tablet for Treatment of HIV-1. Silver profile; 2008Spring: FDA news;2006.11. Reserve bank of India (India).RBI reference rate on4. New York State Department of health (US). Anti-31/07/08.Mumbai:Exchange rate; 2008retroviral therapy. New York :2008.12. World heath organization (Switzerland).Selected5. Guidelines for the Use of Antiretroviral Agents innational health accounts indicators. Geneva: TheHIV-1-Infected Adults and Adolescents. NationalInstitute of Health, Maryland, (US); aidsinfo; world health report; 2006.October 10, 2006.13. World heath organization (Switzerland).Scaling up6. Jacobson MA, Liu L, Bashi HK , Deeks S, Hecht of Antiretroviral Therapy in resource limited setting.FM, Kahn J. Absolute or total lymphocyte count as a Geneva: Guidelines for a public healthmarker for the CD4 T lymphocyte criterion for approach;2002initiating antiretroviral therapy. AIDS 2003;17: 917- 14. Akinola N O, Olasode O, Adediran I. A, Onayemi O,919. Murainah A, Irinoye O. et.al. The Search for a7. Spacek LA, Griswold M, Quinn TC, Moore RD.Predictor of CD4 Cell Count Continues: TotalTotal lymphocyte count and hemoglobin combinedLymphocyte Count Is Not a Substitute for CD4 Cellin an algorithm to initiate the use of highly activeantiretroviral therapy in resource-limited settings.Count in the Management of HIV-InfectedAIDS 2003; 17:1311–1317.Individuals in a Resource-Limited Setting. Clin8. Mahajan AP, Hogan JW, Snyder B, Kumarasamy N, Infec Diseases. 2004; 39:579–581.34
Indian J. Pharm. Pract. 1(2), Jan-Mar, 200915. Farmer P, Léandre F, Mukherjee JS, Claude M, Nevil 2002;34:984-990.P, Smith-Fawzi MC. et.al. Community-based 17.Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwaapproaches to HIV treatment in resource–poor O, Salaniponi FM. Preventing antiretroviral anarchysetting. Lancet 2001;358:404-409in Sub-Saharan Africa. Lancet 2001; 358:410-414.16. Mitty JA, Stone VE, Sands M, Macalino G, Flanigan18. Weidle PJ, Mastro TD, Grant AD, Nkengasong J,T. Directly observed therapy for the treatment ofpeople with human immunodeficiency virus Macharia D. HIV/AIDS treatment and HIV vaccinesinfection: a work in progress. Clin infec diseases for AFRICA. Lancet 2002; 359: 2261-67.35
- Page 1: Indian Journal of Pharmacy Practice
- Page 4 and 5: Indian Journal of Pharmacy Practice
- Page 7 and 8: APTIIndian J. Pharm. Pract. 1(2), J
- Page 10 and 11: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 12 and 13: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 14 and 15: APTIijoppGenesis, Development and P
- Page 16 and 17: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 19 and 20: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 21 and 22: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 23 and 24: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 25 and 26: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 27 and 28: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 29 and 30: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 31 and 32: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 33 and 34: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 35 and 36: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 37 and 38: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 39: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 43 and 44: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 45 and 46: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 47 and 48: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 49 and 50: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 51 and 52: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 53 and 54: pivotal to the rational use of medi
- Page 55 and 56: .leadership” (Cohen, 1984). A stu
- Page 57 and 58: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 59 and 60: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 61 and 62: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 63 and 64: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 65 and 66: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 67 and 68: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 69 and 70: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 71 and 72: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 73 and 74: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 75 and 76: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 77 and 78: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 79 and 80: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 81 and 82: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 83 and 84: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 85 and 86: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 87 and 88: Indian J. Pharm. Pract. 1(2), Jan-M
- Page 89 and 90: Indian J. Pharm. Pract. 1(2), Jan-M
<strong>Indian</strong> J. Pharm. Pract. 1(2), Jan-Mar, 200915. Farmer P, Léandre F, Mukherjee JS, Claude M, Nevil 2002;34:984-990.P, Smith-Fawzi MC. et.al. Community-based 17.Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwaapproaches to HIV treatment in resource–poor O, Salaniponi FM. Preventing antiretroviral anarchysetting. Lancet 2001;358:404-409in Sub-Saharan Africa. Lancet 2001; 358:410-414.16. Mitty JA, Stone VE, Sands M, Macalino G, Flanigan18. Weidle PJ, Mastro TD, Grant AD, Nkengasong J,T. Directly observed therapy for the treatment <strong>of</strong>people with human immunodeficiency virus Macharia D. HIV/AIDS treatment and HIV vaccinesinfection: a work in progress. Clin infec diseases for AFRICA. Lancet 2002; 359: 2261-67.35
Change language